MX2023011853A - Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento del cáncer. - Google Patents

Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento del cáncer.

Info

Publication number
MX2023011853A
MX2023011853A MX2023011853A MX2023011853A MX2023011853A MX 2023011853 A MX2023011853 A MX 2023011853A MX 2023011853 A MX2023011853 A MX 2023011853A MX 2023011853 A MX2023011853 A MX 2023011853A MX 2023011853 A MX2023011853 A MX 2023011853A
Authority
MX
Mexico
Prior art keywords
inhibitors
prmt5
cancer
treatment
methyl transferase
Prior art date
Application number
MX2023011853A
Other languages
English (en)
Spanish (es)
Inventor
James Gail Christensen
Lars Daniel Engstrom
Peter Olson
Original Assignee
Mirati Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirati Therapeutics Inc filed Critical Mirati Therapeutics Inc
Publication of MX2023011853A publication Critical patent/MX2023011853A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023011853A 2021-04-08 2022-04-05 Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento del cáncer. MX2023011853A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163172643P 2021-04-08 2021-04-08
US202163253029P 2021-10-06 2021-10-06
PCT/US2022/023388 WO2022216645A1 (en) 2021-04-08 2022-04-05 Combination therapies using prmt5 inhibitors for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2023011853A true MX2023011853A (es) 2023-12-07

Family

ID=81748438

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011853A MX2023011853A (es) 2021-04-08 2022-04-05 Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento del cáncer.

Country Status (9)

Country Link
US (2) US12171765B2 (cg-RX-API-DMAC7.html)
EP (1) EP4319753A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024513494A (cg-RX-API-DMAC7.html)
KR (1) KR20230167050A (cg-RX-API-DMAC7.html)
AU (1) AU2022254651A1 (cg-RX-API-DMAC7.html)
CA (1) CA3214535A1 (cg-RX-API-DMAC7.html)
IL (1) IL307393A (cg-RX-API-DMAC7.html)
MX (1) MX2023011853A (cg-RX-API-DMAC7.html)
WO (1) WO2022216645A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4304720A1 (en) * 2021-03-11 2024-01-17 Mirati Therapeutics, Inc. Mta-cooperative prmt5 inhibitors
EP4442680A4 (en) * 2021-11-30 2026-05-06 Abbisko Therapeutics Co Ltd Pyrazole derivative, its preparation process and its use in medicine
EP4458812A1 (en) * 2021-12-27 2024-11-06 Medshine Discovery Inc. Pyrazole-1(2h)-phthalazinone compound and application thereof
WO2024022186A1 (zh) * 2022-07-29 2024-02-01 四川科伦博泰生物医药股份有限公司 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途
WO2024027703A1 (zh) * 2022-08-02 2024-02-08 上海艾力斯医药科技股份有限公司 一种prmt5抑制剂、其制备方法及应用
CN120265615A (zh) * 2022-11-29 2025-07-04 正大天晴药业集团股份有限公司 含有二氢酞嗪的化合物
WO2024177416A1 (ko) * 2023-02-22 2024-08-29 단국대학교 천안캠퍼스 산학협력단 Egfr 표적치료제 내성암 치료용 약학 조성물
CN117653635A (zh) * 2023-12-06 2024-03-08 上海市第一妇婴保健院 一种治疗ccne1异常扩增型卵巢癌的药物组合物及其应用
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025157288A1 (zh) * 2024-01-26 2025-07-31 上海湃隆生物科技有限公司 包含prmt5抑制剂和cdk4/6抑制剂的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180271891A1 (en) * 2015-03-11 2018-09-27 The Broad Institute Inc. Selective treatment of prmt5 dependent cancer
JP2021176819A (ja) 2018-07-31 2021-11-11 アステラス製薬株式会社 キナゾリン化合物を有効成分とする医薬組成物
CN120208880A (zh) * 2019-09-12 2025-06-27 米拉蒂医疗股份有限公司 Mta-协同prmt5抑制剂
GEP20247638B (en) * 2019-10-22 2024-07-10 Lupin Ltd Pharmaceutical combination of prmt5 inhibitors

Also Published As

Publication number Publication date
WO2022216645A1 (en) 2022-10-13
AU2022254651A1 (en) 2023-11-02
JP2024513494A (ja) 2024-03-25
CA3214535A1 (en) 2022-10-13
US20220331323A1 (en) 2022-10-20
EP4319753A1 (en) 2024-02-14
US12171765B2 (en) 2024-12-24
KR20230167050A (ko) 2023-12-07
IL307393A (en) 2023-12-01
US20250073241A1 (en) 2025-03-06

Similar Documents

Publication Publication Date Title
BR112022004248A2 (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
GEAP202516803A (en) Bicyclic amines as cdk2 inhibitors
CR20230500A (es) Métodos para inhibir ras
BR112021024999A2 (pt) Inibidores de prmt5
MX2023000735A (es) Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer.
MX2016016115A (es) Metodo para tratar cancer usando una combinacion de inhibidores de chk1 y relacionado con atm y rad3 (atr).
BR112018074621A2 (pt) derivados de pirazolopirimidina como inibidores de quinase
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
BR112022007158A2 (pt) Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
MX2022001004A (es) Inhibidores de enzimas.
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
BR112021006318A2 (pt) terapia de combinação para o tratamento de câncer
CY1124688T1 (el) Θεραπεια πρωτεϊνουριας
MX2024004171A (es) Tratamientos conjuntos que usan inhibidores de la proteina arginina n-metil transferasa 5 (prmt5) para el tratamiento de cancer.
CO2024009144A2 (es) Inhibidores de cinasa met
MX2022004270A (es) Inhibidores de aldosa reductasa para el tratamiento de la deficiencia de fosfomannomutasa 2.
BR112022003768A2 (pt) Compostos inibidores de perk
BR112017022653A2 (pt) ?métodos para o tratamento ou para a prevenção de uma doença, da artrite reumatoide, da prostatite e da bph?
CL2021000892A1 (es) Avexitida para el tratamiento de la hipoglucemia hiperinsulinémica
MX2021009863A (es) Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer.
BR112020019624A8 (pt) Método para tratar a hipoglicemia pós-prandial
BR112018073627A2 (pt) método para tratar câncer em um paciente